Nanoform Finland Plc – Managers’ transactions – Peter Hänninen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Pressmeddelande

Nanoform Finland Plc – Managers’ transactions – Peter Hänninen

Company release

Nanoform Finland Plc

September 13, 2023

17:30 Finnish time / 16:30 Swedish time

Nanoform Finland Plc – Managers’ transactions – Peter Hänninen

Helsinki, Finland Manager’s transaction related to Nanoform Finland Plc General Counsel Peter Hänninen’s acceptance of stock options of Nanoform Finland Plc:

Nanoform Finland Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Peter Hänninen

Position: Other senior manager

 Issuer: Nanoform Finland Oyj

LEI: 743700JJO2NU8LBS1592

Notification type: INITIAL NOTIFICATION

Reference number: 37722/5/4

____________________________________________

Transaction date: 2023-09-13

Outside a trading venue

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Name of the instrument: Nanoform Finland Oyj stock option 1/2023

Nature of transaction: ACCEPTANCE OF A STOCK OPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 50000 Unit price: 0 EUR

Aggregated transactions (1):

Volume: 50000 Volume weighted average price: 0 EUR

For further information, please contact:

Peter Hänninen

General Counsel

[email protected]

+358 50 353 0408

For investor relations queries, please contact:

Henri von Haartman

Director of Investor Relations

[email protected]

+46 7686 650 11

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform’s platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services. Nanoform’s capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information, please visit www.nanoform.com.

Bifogade filer

Nyheter om Nanoform

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!

STÄNG X
Populär sparapp – över 500 000 nedladdningar
Många och höga externa omdömen
Högst grad av diversifiering
Perfekt för regelbundet månadssparande
KOM IGÅNG

Nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 får automatiskt 50 procent rabatt på Optis avgift i 3 månader

Om aktien Nanoform

Senaste nytt